Please login to the form below

Not currently logged in
Email:
Password:

Ablynx

This page shows the latest Ablynx news and features for those working in and with pharma, biotech and healthcare.

Duchenne UK backs Evox dystrophin delivery project

Duchenne UK backs Evox dystrophin delivery project

de Fougerolles, who joined the company last year from Ablynx.

Latest news

More from news
Approximately 8 fully matching, plus 29 partially matching documents found.

Latest Intelligence

  • 30 Women Leaders in UK Healthcare (part 2) 30 Women Leaders in UK Healthcare (part 2)

    corporate roles for Vertex and Ablynx.

  • Deal Watch January 2018

    bid for Ablynx in December, which the Ablynx Board rejected.  Novo Nordisk's particular interest was in lead asset caplacizumab, a Nanobody therapeutic which inhibits von Willebrand factor (vWF) for the ... Acquisition company. 7, 000. Ablynx/Sanofi.

  • Deal Watch November 2015 Deal Watch November 2015

    410. Ablynx. Novo Nordisk. Discovery collaboration, licence. Multi specific Nanobody drug candidates in undisclosed TA with option to expand to second Nanobody programme.

  • Deal Watch table for February 2014 Deal Watch table for February 2014

    25, 000. Ablynx / Merck &Co. Collaboration. Nanobody candidates to target “immune checkpoint modulators”.

  • Pharma deals during February 2014 Pharma deals during February 2014

    It is has been a busy month for Merck &Co. Belgian-based Ablynx has signed a second exclusive collaboration and licensing deal with the company to focus on the discovery and ... Under the terms of the agreement, Ablynx will receive an upfront payment of

More from intelligence
Approximately 0 fully matching, plus 9 partially matching documents found.

Latest appointments

  • PureTech Health appoints new chief financial officer PureTech Health appoints new chief financial officer

    Muijrers has worked with pharmaceutical clients such as Kite Pharma, Ablynx and Juno Therapeutics, and said: “I am thrilled to join PureTech Health, one of the most exiciting and unique biopharma

  • Apitope strengthens its board with new director Apitope strengthens its board with new director

    He has also served on several boards including Ablynx, Evotec and Acambis.

  • Ablynx reshuffles its board again Ablynx reshuffles its board again

    Dr Greig has been non-executive director of Ablynx since 2012, and has been unanimously elected by the board to be the biotech’s new chairman. ... Dr Edwin Moses, chief executive officer of Ablynx, said: “We are very fortunate to have a very suitable

  • Robert Freisen joins Ablynx Robert Freisen joins Ablynx

    Ablynx, recently acquired by Sanofi, has appointed Robert Freisen to the role of chief scientific officer, who will head the biopharma’s scientific research and technology activities. ... He said: “I have long admired Ablynx and am excited to join

  • Novo Nordisk target Ablynx reshuffles its board Novo Nordisk target Ablynx reshuffles its board

    Biopharmaceutical group Ablynx has made some changes to its board of directors after recently declining a takeover proposal for the second time from Novo Nordisk. ... Heading up the board is Ablynx’s non-executive director Dr Bo Jesper Hensen (pictured)

More from appointments
Approximately 5 fully matching, plus 6 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Market Access Transformation

Market Access Transformation (MAT), founded by industry veterans Baiju Aurora and Paul Howard, specializes in developing cutting edge technologies that...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics